Introduction

COPD is a disease state characterized by the presence of chronic airflow limitation that progresses slowly over a period of years and is not fully reversible (1). A systematic review and meta-analysis estimated the global prevalence of physiologically defined COPD in adults aged !40 years to
be approximately 9-10% (2) . In Japan, a spirometry-based study conducted in the year 2000 conservatively estimated the prevalence of COPD to be at least 8.6% in Japanese patients, especially those who need frequent treatment and those with nocturnal symptoms.
In Europe, studies have shown formoterol to have beneficial effects at dosages of 4.5, 9 and 18 μg twice daily (bid) in patients with COPD (9, 10) . However, the effects of formoterol on lung functions and symptoms have never been investigated in Japanese patients with COPD. The aim of this randomized, controlled, crossover study was to evaluate the efficacy and safety of three dosages of formoterol (4.5, 9 and 18 μg bid), compared with placebo, for 7 days in Japanese patients with COPD. 
Methods
Patients
Statistical analysis
An improvement of 4% of predicted in FEV1 compared with placebo has been regarded as clinically meaningful (11) , and corresponds to an increase in mean FEV1 of 8% compared with placebo in the target population in this study. Hence, a total of 29 patients completing all study treatments was regarded as necessary to detect the 8% difference with the power of 80% and a one-sided 2.5% significance level,
F i g u r e 1 . F l o w d i a g r a m o f p a t i e n t d i s p o s i t i o n .
assuming that the standard deviation of log-transformed FEV1 was 0.10 (9) . Allowing for withdrawals, a total of 37 patients was the target sample size for randomization in this study.
The primary analysis set for efficacy was the full analysis set (FAS) 
Results
Patient characteristics
A total of 69 clinically diagnosed COPD patients were screened in the study. Of these, 32 showed an FEV1 of more than 70% of predicted and one had an adverse event prior to randomization. Subsequently, 36 patients were randomized to treatment. Figure 1 shows Fig. 2A) . (Fig. 2B) . (Fig. 2C) .
Secondary variables
Post-dose IC on the last day of treatment was significantly higher for all formoterol dosages compared with placebo. A slight increase in the estimate values of the ratio to placebo was observed as the formoterol dosage increased. Mean 1hour post-dose IC for the 18 μg bid dosage was significantly higher than for 4.5 μg bid (p<0.05)
The values of morning and evening PEF were shown in (Fig. 3B) .
The number of as-needed short-acting β2-agonist inhalations (as day total) was significantly lower at the 4. 5 (1) . The primary efficacy analysis showed all formoterol dosages to be significantly superior to placebo in improving FEV1 in these patients, with no significant differences among the three dosages. t o r y c a p a c i t y ; b i d : t wi c e d a i l y .   T a b l e 3 . Mo r n i n g / E v e n i n g P E F F o l l o wi n g 1 We e k o f T r e a t  me n t wi t h F o r mo t e r o l 4 . 5 , 9 o r 1 8 g B i d o r P l a c e b o ( F formoterol studies for COPD in European countries (9, 10 (9, 10) . Similarly, other clinical trials in patients with COPD have found formoterol to be generally well tolerated (10, 14, 20) . However, concerns have been raised about the cardiovascular safety of inhaled β2-agonists in general due to the presence in the literature of reports of adverse events in patients with obstructive airway disease (21, 22) . A review of the cardiovascular safety of β2-agonists in patients with obstructive lung disease concluded that these agents must always be used with caution in patients with cardiovascular disease as they may precipitate the concomitant cardiac disease (21) .
F i g u r e 2 . ( A) F E V1 , ( B ) F VC a n d ( C) I C a f t e r 1 we e k o f t r e a t me n t wi t h f o r mo t e r o l 4 . 5 , 9 o r 1 8 μ g b i d . Da t a a r e e x p r e s s e d a s a d j u s t e d g e o me t r i c me a n s , a n d t h e % o f t h e v a l u e s i n t h e p l a c e b o g r o u p . E r r o r b a r s i n d i c a t e t h e 9 5 % c o n f i d e n c e i n t e r v a l . Ab b r e v i a t i o n s ; F E V1 : f o r c e d e x p i r a t o r y v o l u me i n o n e s e c o n d ; F VC: f o r c e d v i t a l c a p a c i t y ; I C: i n s p i r a
In 
